Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger.

BMC Pediatr

Dipartimento di Pediatria 1, Ospedale Infantile Regina Margherita, Regina Margherita Children's Hospital, Citta' della Salute e della Scienza di Torino, Piazza Polonia 94, 10126, Turin, Italy.

Published: February 2017

Background: Bullous pemphigoid (BP) is a blistering skin disorder infrequent in infancy and rarely reported in medical literature.

Case Presentation: Here we describe three cases of BP which were referred to our department in the last 15 years. Two of them developed an eruption of bullous lesions just a few days after vaccination for diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae B. The third patient developed the same blistering lesions shortly after herpetic stomatitis. In all three cases, clinical diagnosis was confirmed by histological examination which showed subepidermal bullae with a dermal inflammatory infiltrate, and direct immunofluorescence of perilesional skin showed linear IgG and C3 deposits along the basement membrane zone. Immunoblot assay was positive for BP antigen 180. Treatment with oral prednisone was instituted and the lesions resolved in two out of three patients; the third one was treated with an immunosuppressive agent (tacrolimus) and corticosteroid and subsequently with intravenous immunoglobulin and plasmapheresis, due to an underlying complex autoimmune disease.

Conclusion: Although the mechanism of induction of BP is still unclear, the close relationship between trigger events (immunization or viral infection) and onset of the disease arises a possible association.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322655PMC
http://dx.doi.org/10.1186/s12887-017-0813-0DOI Listing

Publication Analysis

Top Keywords

bullous pemphigoid
8
three cases
8
three
4
three case
4
case reports
4
reports post
4
post immunization
4
immunization post
4
post viral
4
viral bullous
4

Similar Publications

Objectives: This study aimed to evaluate the efficacy of low-dose interleukin (IL-2) treatment for bullous pemphigoid (BP) caused by anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors.

Methods: Low-dose IL-2 treatment was standardized for BP. The Bullous Pemphigoid Disease Area Index (BPDAI), 5D-Itch Scale (5D-IS), and Dermatology Life Quality Index (DLQI) were recorded before and after treatment, and hexachromatic lymphocytes, regulatory T cells (Treg cells), and cytokines were measured.

View Article and Find Full Text PDF

Bullous pemphigoid (BP) is the most prevalent autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and manifests with pruritus and localized or, most commonly, generalized bullous lesions. Numerous studies have established the association between BP and oral antidiabetic agents, particularly dipeptidyl peptidase 4 (DPP4) inhibitors, diuretics, and certain antibiotics, notably levofloxacin and cephalexin.

View Article and Find Full Text PDF

Bullous pemphigoid (BP) is a rare autoimmune blistering disease characterised by autoantibodies against basal skin membrane antigens. Although the condition's aetiology remains unclear, recent cases have raised suspicions of an association with immunisation. In this study, we present a case of BP onset in a four-month-old infant following routine vaccination.

View Article and Find Full Text PDF

Macrophages in inflammatory skin diseases and skin tumors.

Front Immunol

December 2024

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Article Synopsis
  • - Macrophages are key immune cells that play diverse roles in the body, especially in the skin, which is the largest immune organ and is crucial for studying various skin-related conditions.
  • - This review focuses on recent findings about macrophages in inflammatory skin diseases like atopic dermatitis and psoriasis, as well as skin tumors such as melanoma and cutaneous T-cell lymphoma.
  • - The goal is to enhance understanding of how macrophages contribute to these diseases and explore potential new treatments targeting them.
View Article and Find Full Text PDF

We present the case of a 36-year-old paraplegic woman with a history of spinal cord injury who developed a generalized blistering rash, later diagnosed as bullous pemphigoid (BP). During her hospitalization, she was treated with prednisone and rituximab infusions, transitioning to maintenance therapy with topical steroids, doxycycline, and nicotinamide. A year later, she presented with concerns about a BP flare on her feet.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!